Responsibility for planning and evaluation is vested in the Lombardi Comprehensive Cancer Center (Lombardi) Director. Planning and evaluation was previously managed by the Associate Director for Administration and Planning (ADAP), with input from the Shared Resources (SRs) Director and programmatic reviews by Program Leadership and the Executive Committee. Following a strategic planning process in 2008, the Director and the Senior Operational Leadership Team (SOLT) now oversee the current planning and evaluation process, with advice from the Associate Directors, the Program Leaders, the Executive Advisory Committee (EAC) and the External Scientific Advisory Committee (ESAC). This has led to changes in several programs and shared resources. At the time of the last competitive CCSG renewal, the Cancer Center Director relied upon the Lombardi Executive Committee for the oversight of Cancer Center activities. This large Committee generally met weekly with the Director to discuss and coordinate scientific recruitment and administrative activities. With the arrival of Dr. Weiner, two new Senior Leadership positions were established, which specifically Include the tasks of planning and evaluation. Dr. Peter Shields was appointed as Deputy Director, and V. Craig Jordan joins Lombardi on July 1, 2009 as Scientific Director. Dr. Weiner separated the functions of the single Executive Committee Into the SOLT and EAC. The SOLT consists of Drs. Weiner, Shields (Deputy Director), Jordan (effective July 1, in his role as Scientific Director), Marshall (Clinical Director), and Mr. Michael Vander Hoek (Associate Director for Administration and Planning). This group meets weekly to address all operational Issues that affect the Cancer Center. The EAC was established to strengthen inter-departmental and transdisciplinary collaborations and to receive important operational feedback that can contribute to the success of the Cancer Center. The EAC meets quarterly. This committee includes a representative from Georgetown University Hospital (GUH) administration, the Department Chairs in the Lombardi Sector, all of whom have an undiluted cancer focus, and other cancer-related departments that reside within GUMC. Dr. Weiner also established regular meetings of the Associate Directors (ADs), who meet monthly to review the progress of Lombardi in the context of the CCSG, conduct planning and evaluation of Lombardi activities, oversee developmental funds, and foster collaborations across programs and disciplines. As before. Program Leaders also meet monthly to provide the SOLT with Lombardi updates and receive feedback on Lombardi activities, vet new Lombardi membership, review Program membership, review shared resource activities, and discuss new collaborative activities. In response to a formal strategic planning process in 2008, six programs and 12 shared resources were reconfigured and identified. This effort led to the identification of cross-cutting initiatives, the redefinition of each programs' aims, recruitment plans, and prioritization of resource allocation. Future plans include fostering transdisciplinary, multi-investigator research, emphasizing cross-cutting initiatives such as minority and health disparities research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA051008-19
Application #
8375504
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
19
Fiscal Year
2012
Total Cost
$15,909
Indirect Cost
Name
Georgetown University
Department
Type
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2017) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother :
Rao, Guanhua; Pierobon, Mariaelena; Kim, In-Kyu et al. (2017) Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Sci Rep 7:7066
Lynce, Filipa; Barac, Ana; Tan, Ming T et al. (2017) SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function. Oncologist 22:518-525
Vietsch, Eveline E; Graham, Garrett T; McCutcheon, Justine N et al. (2017) Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet 218-219:39-50
Walker, Logan C; Marquart, Louise; Pearson, John F et al. (2017) Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. Eur J Hum Genet 25:432-438
Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A et al. (2017) RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc 7:
DeVito, Stephen; Woodrick, Jordan; Song, Linze et al. (2017) Mutagenic potential of hypoxanthine in live human cells. Mutat Res 803-805:9-16
Wang, Hongkun; Wang, Ying; Kota, Krishna K et al. (2017) Strong associations between chromosomal aberrations in blood lymphocytes and the risk of urothelial and squamous cell carcinoma of the bladder. Sci Rep 7:13493
Parodi, Daniela A; Greenfield, Morgan; Evans, Claire et al. (2017) Alteration of Mammary Gland Development and Gene Expression by In Utero Exposure to Cadmium. Int J Mol Sci 18:
Casero, David; Gill, Kirandeep; Sridharan, Vijayalakshmi et al. (2017) Space-type radiation induces multimodal responses in the mouse gut microbiome and metabolome. Microbiome 5:105

Showing the most recent 10 out of 997 publications